COMP <GO>
EQ vs ANIX // DIVIDEND YIELD & FCF PAYOUT SAFETY
Equillium Inc. (NASDAQ) VS. Anixa Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: EQ 0
— ANIX 4
■ METRIC PARITY
LAST: $1.37 (-3.52%) • MKT CAP: $111.3M
dividend-safety
0.00%
LAST: $3.12 (-5.45%) • MKT CAP: $114.7M
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EQ VS. ANIX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EQ | ANIX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -20.48% | -6.25% | -14.23 | ANIX | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | 3/9 | -2.00 | ANIX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.8 | 56.3 | -12.52 | ANIX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $111.3M | $114.7M | -$3.4M | ANIX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EQ REV | ANIX REV | EQ GROSS % | ANIX GROSS % | EQ FCF | ANIX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$22.8M | -$7.2M |
| FY 2024 | $41.1M | $210.0K | — | — | -$19.1M | -$7.3M |
| FY 2023 | $36.1M | $210.0K | — | — | -$21.8M | -$6.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EQ // BETA —
ANIX // BETA —